Immune hemolytic disease of the fetus and newborn is a condition in which there is the premature destruction of fetal or neonatal red cells due to maternal alloantibody against red cell antigen inherited from father. We report the case of Hemolytic disease of fetus and newborn (HDFN) due to anti-E and anti-Fya antibody. Blood grouping was done using the conventional tube technique. Rh and Kell phenotyping of the patient and her husband performed by column agglutination and Duffy phenotyping were done by the conventional tube technique. Direct antiglobulin test was performed by column agglutination technique. Antibody screening and identification were done. Anti-E and Anti-Fya were identified with titer of Anti-E: 1:64 and Anti-Fy a : 1:256. The patient's neonate developed jaundice. Phototherapy was given. Bilirubin stabilized and discharged on the 12 th day.
Background: Fresh frozen plasma is commonly used in tertiary care hospitals. These are used to manage conditions such as coagulation derangements. Unnecessary use of fresh frozen plasma (FFP) is known to increase the risk of side effects in plasma transfusing patients like anaphylaxis, transfusion related acute lung injury (TRALI) and risk of transfusion transmitted infections etc. So judicious use of plasma is extremely important where its benefits outweigh its potential risks.Methods: Prospective observational study conducted over a period of six month. The following data were collected; provisional clinical diagnosis, indication of FFP’S, coagulation profile and gender of the patients. We evaluated all FFP transfusions, classified them as appropriate or inappropriate according to fresh frozen plasma transfusion guidelines of Directorate general of health services (DGHS).Results: A total of 808 FFP units were issued (474 units to males and 334 units to females) over a period of 6 months. Out of these, 15% (122 units) of FFP’s were issued to intensive care unit (ICU) patients, 12.87% (104 units) to paediatrics ward, 12.25% (99 units) to emergency ward which include patients with upper GI bleed and lower GI bleed , 6.8% (55 units) to obstetrics patients, 6.18% (50 units) to orthopaedics, 4.45% (36 units) to road traffic accident patients, 4.20% (34 units) to Hepatic failure patients, 3.09% (25 units) to Cardiothoracic and vascular surgery (CTVS), 2.97% (24 units) to oncology patients, 2.47% (20 units) to snake bite patients, 1.23 % (10 units) to dengue patients, 1.11% (9 units) to Haemophilia patients, 27.38% units were issued to the patients were indication for FFP transfusion was not known.Conclusions: study showed that 66.44% were appropriate and 33.56% were inappropriate use of FFP’s in patients. This highlights the pitfalls in use of FFP among clinicians and for that matter there is need of awareness and understanding the transfusion medicine by clinicians.
Scarcity of blood and blood products is frequently encountered in health care institutions. Increasing awareness among young people about blood donations can serve as an important pool of potential blood donors for hospitals. Aim: To assess the awareness of blood donations among voluntary and replacement donors. Material And Methods: a prospective study conducted in department of immunohematology and transfusion medicine LD (Lal ded)Hospital a tertiary care hospital In Srinagar,Jammu and Kashmir,India. The study was carried over a period of one year from August 2021 to July 2022. Results: In this present study 64.3% were voluntary donors and 35.7% were replacement donors.22.8% the height percentage among donors show apprehension of weakness after blood donations as the main reason for not donating blood. Followed by other reasons as well. 0.57% as least percentage of donors due to there low hemoglobulin as a reason for not donating blood.This reason was mainly seen among female donors. Conclusion: There is a critical need for training and culture building activities and programs to increase people's awareness and improve their attitude towards blood donation
Plateletpheresis is used to obtain platelets from volunteer donors, patient's family members,or donor with HLA or platelet antigen compatible phenotypes. To analyze the adverse reactions due to single donor platelet Aim: pheresis. Materials and Methods:This was a prospective observational study conducted over a period of one year from September 2018 to August 2019 in the department of Immunohematology and Blood Transfusion Medicine, GMC Jammu. A total of 157 plateletpheresis procedures were performed after taking informed and written consent from the donor. The donors were selected as per the guidelines of Director General of Health Services (DGHS). Single arm procedure was used.All the procedures were performed on Fresenius kabiCom.tec op 5/07.08 by intermittent flow centrifugation (IFC). The adverse events (AE's) were classified as donor related and kit/equipment related. A total Results: of 10 AE's were noted of which 6 (60%) events were associated with donors and 4 (40%) events were owned to fault in the kit/equipment.Donor related 6 AE's include citrate toxicity[n=3(50%)], vasovagal reactions [n=2(33.33%)] and hematoma [n=1(16.67%)].Machine related 4 AE's include leakage in the kit[n=3(75%)] and interface error [n=1(25%)]. Discussion and Conclusion: Our study showed (n=6)3.82% donor reactions and equipment related (n=4) 2.54% reactions. Apheresis donations performed on cell separators are safe. The percentage of reactions in our study was 6.36% and no serious adverse reaction was noted .But precautions and close monitoring helps to reduce such mild forms of reactions.Increasing demand of platelet transfusions for patients had led to accelerated use of Apheresis, cause of higher yield of platelets obtained from single donor.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.